A new dimension of FDG-PET interpretation: Assessment of tumor biology

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 6, 2011, Pages 1158-1170

  Kwee, Thomas C ^a   Basu, Sandip ^b,c   Saboury, Babak ^c   Ambrosini, Valentina ^d   Torigian, Drew A ^c   Alavi, Abass ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TATA MEMORIAL HOSPITAL   (India)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

False negative; FDG PET; Tumor biology

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131;

CANCER DIAGNOSIS; DIAGNOSTIC VALUE; DRUG UPTAKE; FALSE NEGATIVE RESULT; HUMAN; NEOPLASM; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; TUMOR VOLUME;

FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 79958036100     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1713-9     Document Type: Review

References (62)

1. S Basu A Alavi 2008 Unparalleled contribution of 18F-FDG PET to medicine over 3 decades J Nucl Med 49 17N 21N 18832112 10.2967/jnumed.108.050401 (Pubitemid 351793447)
2. EM Rohren TG Turkington RE Coleman 2004 Clinical applications of PET in oncology Radiology 231 305 332 15044750 10.1148/radiol.2312021185 (Pubitemid 38552885)
3. RJ Gillies I Robey RA Gatenby 2008 Causes and consequences of increased glucose metabolism of cancers J Nucl Med 49 Suppl 2 24S 42S 18523064 10.2967/jnumed.107.047258 1:CAS:528:DC%2BD1cXotFahurg%3D (Pubitemid 351948035)
4. JW Fletcher B Djulbegovic HP Soares BA Siegel VJ Lowe GH Lyman, et al. 2008 Recommendations on the use of 18F-FDG PET in oncology J Nucl Med 49 480 508 18287273 10.2967/jnumed.107.047787 (Pubitemid 351355215)
5. H Jadvar A Alavi SS Gambhir 2009 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization J Nucl Med 50 1820 1827 19837767 10.2967/jnumed.108.054098
6. S Basu R Kumar A Mavi A Alavi 2009 Exploring tumor biology with fluorodeoxyglucose-positron emission tomography imaging in breast carcinoma PET Clin 4 381 389 10.1016/j.cpet.2009.12.001
7. DJ Samson CR Flamm ED Pisano N Aronson 2002 Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad Radiol 9 773 783 12139091 10.1016/S1076-6332(03)80347-1 (Pubitemid 34761360)
8. R Kumar A Chauhan H Zhuang P Chandra M Schnall A Alavi 2006 Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer Breast Cancer Res Treat 98 267 274 16555126 10.1007/s10549-006- 9159-2 (Pubitemid 44195596)
9. S Basu W Chen J Tchou A Mavi T Cermik B Czerniecki, et al. 2008 Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization Cancer 112 995 1000 18098228 10.1002/cncr.23226 1:CAS:528:DC%2BD1cXjs1eqsLo%3D (Pubitemid 351304582)
10. CJ Jaskowiak JA Bianco SB Perlman JP Fine 2005 Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values J Nucl Med 46 424 428 15750154 (Pubitemid 43093150)
11. W Wang SM Larson M Fazzari SK Tickoo K Kolbert G Sgouros, et al. 2000 Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer J Clin Endocrinol Metab 85 1107 1113 10720047 10.1210/jc.85.3.1107 1:CAS:528:DC%2BD3cXisFOru7Y%3D (Pubitemid 32269357)
12. RJ Robbins Q Wan RK Grewal R Reibke M Gonen HW Strauss, et al. 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning J Clin Endocrinol Metab 91 498 505 16303836 10.1210/jc.2005-1534 1:CAS:528: DC%2BD28XhsFKntb0%3D (Pubitemid 43236915)
13. M Weiler-Sagie O Bushelev R Epelbaum EJ Dann N Haim I Avivi, et al. 2010 (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients J Nucl Med 51 25 30 20009002 10.2967/jnumed.109.067892
14. H Schöder A Noy M Gönen L Weng D Green YE Erdi, et al. 2005 Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma J Clin Oncol 23 4643 4651 15837966 10.1200/JCO.2005.12.072 (Pubitemid 46224066)
15. JY Ngeow RH Quek DC Ng SW Hee M Tao LC Lim, et al. 2009 High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma Ann Oncol 20 1543 1547 19474116 10.1093/annonc/mdp030 1:STN:280:DC%2BD1MrnsVGgsg%3D%3D
16. M Karam A Ata K Irish PJ Feustel FM Mottaghy SG Stroobants, et al. 2009 FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome Nucl Med Commun 30 770 778 19657307 10.1097/MNM.0b013e32832e0c13
17. A Gallamini M Hutchings L Rigacci L Specht F Merli M Hansen, et al. 2007 Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study J Clin Oncol 25 3746 3752 17646666 10.1200/JCO.2007.11.6525 1:CAS:528:DC%2BD2sXhtVeqt7fE (Pubitemid 47372616)
18. C Haioun E Itti A Rahmouni P Brice JD Rain K Belhadj P Gaulard, et al. 2005 [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome Blood 106 1376 1381 15860666 10.1182/blood-2005-01-0272 1:CAS:528: DC%2BD2MXosVejt7k%3D (Pubitemid 41129604)
19. IJ Liu MB Zafar YH Lai GM Segall MK Terris 2001 Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer Urology 57 108 111 11164153 10.1016/S0090- 4295(00)00896-7 1:STN:280:DC%2BD3M3is1emtQ%3D%3D (Pubitemid 32065829)
20. J Sung JI Espiritu GM Segall MK Terris 2003 Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer BJU Int 92 24 27 12823377 10.1046/j.1464-410X.2003.04297.x 1:STN:280:DC%2BD3s3psF2hug%3D%3D (Pubitemid 36843022)
21. H Schöder K Herrmann M Gönen H Hricak S Eberhard P Scardino, et al. 2005 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy Clin Cancer Res 11 4761 4769 16000572 10.1158/1078-0432. CCR-05-0249 (Pubitemid 41557196)
22. JA Richter M Rodríguez J Rioja I Peñuelas J Martí-Climent P Garrastachu, et al. 2010 Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment Mol Imaging Biol 12 210 217 19543774 10.1007/s11307-009-0243-y
23. N Oyama H Akino Y Suzuki H Kanamaru Y Miwa H Tsuka, et al. 2002 Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer Mol Imaging Biol 4 99 104 14538053 10.1016/S1095-0397(01)00065-6 (Pubitemid 34272714)
24. M Fiorentino E Capizzi M Loda 2010 Blood and tissue biomarkers in prostate cancer: state of the art Urol Clin North Am 37 131 141 20152526 10.1016/j.ucl.2009.11.006
25. JW Park JH Kim SK Kim KW Kang KW Park JI Choi, et al. 2008 A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma J Nucl Med 49 1912 1921 18997056 10.2967/jnumed.108.055087
26. E Hatano I Ikai T Higashi S Teramukai T Torizuka T Saga, et al. 2006 Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection World J Surg 30 1736 1741 16850145 10.1007/s00268-005-0791-5 (Pubitemid 44411232)
27. T Torizuka N Tamaki T Inokuma Y Magata S Sasayama Y Yonekura, et al. 1995 In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET J Nucl Med 36 1811 1817 7562048 1:STN:280:DyaK28%2FgslKgsw%3D%3D
28. EP Krenning DJ Kwekkeboom WH Bakker WA Breeman PP Kooij HY Oei, et al. 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 716 731 8404961 10.1007/BF00181765 1:STN:280: DyaK2c%2FgvFWjug%3D%3D (Pubitemid 23284773)
29. S Hoegerle C Altehoefer N Ghanem G Koehler CF Waller H Scheruebl, et al. 2001 Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors Radiology 220 373 380 11477239 1:STN:280:DC%2BD3MvjtFWksA%3D%3D (Pubitemid 32667172)
30. M Gabriel C Decristoforo D Kendler G Dobrozemsky D Heute C Uprimny, et al. 2007 [68Ga]DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 508 518 17401086 10.2967/jnumed.106.035667 1:CAS:528:DC%2BD2sXhtVert7jF (Pubitemid 47571404)
31. D Campana V Ambrosini R Pezzilli S Fanti AM Labate D Santini, et al. 2010 Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors J Nucl Med 51 353 359 20150249 10.2967/jnumed.109. 066662
32. V Ambrosini D Campana L Bodei C Nanni P Castellucci V Allegri, et al. 2010 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors J Nucl Med 51 669 673 20395323 10.2967/jnumed.109.071712
33. S Adams R Baum T Rink PM Schumm-Dräger KH Usadel G Hör 1998 Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors Eur J Nucl Med 25 79 83 9396878 10.1007/s002590050197 1:CAS:528:DyaK2sXnvVGru7o%3D (Pubitemid 28107907)
34. D Wild HR Mäcke B Waser JC Reubi M Ginj H Rasch, et al. 2005 [68Ga]DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur J Nucl Med Mol Imaging 32 724 15551131 10.1007/s00259-004-1697-4 (Pubitemid 40897499)
35. T Binderup U Knigge A Loft J Mortensen A Pfeifer B Federspiel, et al. 2010 Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET J Nucl Med 51 704 712 20395333 10.2967/jnumed.109.069765
36. T Binderup U Knigge A Loft B Federspiel A Kjaer 2010 18F- fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors Clin Cancer Res 16 978 985 20103666 10.1158/1078-0432.CCR-09-1759 1:CAS:528:DC%2BC3cXhs1aqs7k%3D
37. E Garin F Le Jeune A Devillers M Cuggia AS de Lajarte-Thirouard C Bouriel, et al. 2009 Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors J Nucl Med 50 858 864 19443590 10.2967/jnumed.108.057505 1:CAS:528:DC%2BD1MXnvF2rurY%3D
38. D Rubello L Rampin C Nanni E Banti M Ferdeghini S Fanti, et al. 2008 The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study Eur J Surg Oncol 34 581 586 17892923 1:STN:280:DC%2BD1c3mtVOgug%3D%3D (Pubitemid 351514892)
39. BG Conry ND Papathanasiou V Prakash I Kayani M Caplin S Mahmood, et al. 2010 Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma Eur J Nucl Med Mol Imaging 37 49 57 19662413 10.1007/s00259-009-1204-z 1:CAS:528:DC%2BD1MXhsFCktLrJ
40. K Higashi Y Ueda H Seki K Yuasa M Oguchi T Noguchi, et al. 1998 Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma J Nucl Med 39 1016 1020 9627336 1:STN:280:DyaK1c3ovFShtw%3D%3D (Pubitemid 28270118)
41. B Goudarzi HA Jacene RL Wahl 2008 Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT J Nucl Med 49 1585 1592 18794276 10.2967/jnumed.108.052712
42. MV Padma S Said M Jacobs DR Hwang K Dunigan M Satter, et al. 2003 Prediction of pathology and survival by FDG PET in gliomas J Neurooncol 64 227 237 14558598 10.1023/A:1025665820001 1:STN:280:DC%2BD3svotVWgsQ%3D%3D (Pubitemid 37203463)
43. EA Kidd CR Spencer PC Huettner BA Siegel F Dehdashti JS Rader, et al. 2009 Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake Cancer 115 3548 3554 19472399 10.1002/cncr.24400
44. EA Kidd BA Siegel F Dehdashti PW Grigsby 2007 The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival Cancer 110 1738 1744 17786947 10.1002/cncr.22974 (Pubitemid 47557298)
45. L Pan P Gu G Huang H Xue S Wu 2009 Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis Eur J Gastroenterol Hepatol 21 1008 1015 19352191 10.1097/MEG.0b013e328323d6fa
46. H Kato M Nakajima M Sohda N Tanaka T Inose T Miyazaki, et al. 2009 The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer Cancer 115 3196 3203 19472406 10.1002/cncr.24399
47. B Sepesi DP Raymond M Polomsky TJ Watson VR Litle CE Jones, et al. 2009 Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer J Gastrointest Surg 13 2121 2127 19795177 10.1007/s11605-009-1038-9
48. Scully RE. International histological classification of tumors: histological typing of ovarian tumors. Geneva: World Health Organization; 1999.
49. C Nanni D Rubello M Farsad P De Iaco M Sansovini P Erba, et al. 2005 (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients Eur J Surg Oncol 31 792 797 15893908 10.1016/j.ejso.2005.02.029 1:STN:280:DC%2BD2MvlvVChtg%3D%3D (Pubitemid 41194659)
50. LJ Havrilesky SL Kulasingam DB Matchar ER Myers 2005 FDG-PET for management of cervical and ovarian cancer Gynecol Oncol 97 183 191 15790456 10.1016/j.ygyno.2004.12.007 (Pubitemid 40403692)
51. R Kumar A Alavi 2004 PET imaging in gynecologic malignancies Radiol Clin North Am 42 1155 1167 15488564 10.1016/j.rcl.2004.08.006 (Pubitemid 39361466)
52. S Fenchel D Grab K Nuessle J Kotzerke A Rieber R Kreienberg, et al. 2002 Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings Radiology 223 780 788 12034950 10.1148/radiol.2233001850 (Pubitemid 34547598)
53. A Rieber K Nüssle I Stöhr D Grab S Fenchel R Kreienberg, et al. 2001 Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings AJR Am J Roentgenol 177 123 129 11418411 1:STN:280:DC%2BD3MznsFKlsQ%3D%3D (Pubitemid 32578064)
54. PJ Woodward K Hosseinzadeh JS Saenger 2004 From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation Radiographics 24 225 246 14730048 10.1148/rg.241035178 (Pubitemid 38134607)
55. YT Huang JC Lee AS Kumar 2009 Variable F-18 fluorodeoxyglucose avidity of metastatic recurrent adult granulosa cell tumor Clin Nucl Med 34 710 712 19893410 10.1097/RLU.0b013e3181b539e4 1:STN:280:DC%2BD1Mjkt1GmtQ%3D%3D
56. M Picchio S Sironi C Messa G Mangili C Landoni L Gianolli 2003 Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment Q J Nucl Med 47 77 84 12865867 1:STN:280:DC%2BD3szjtlKiug%3D%3D (Pubitemid 36998713)
57. S Risum C Høgdall A Loft AK Berthelsen E Høgdall L Nedergaard, et al. 2007 The diagnostic value of PET/CT for primary ovarian cancer: a prospective study Gynecol Oncol 105 145 149 17229460 10.1016/j.ygyno.2006.11.022 (Pubitemid 46454333)
58. Y Yamamoto H Oguri R Yamada N Maeda S Kohsaki T Fukaya 2008 Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography Int J Gynecol Obstet 102 124 127 10.1016/j.ijgo.2008.02.019
59. DC Jung HJ Choi W Ju SC Kim KG Choi 2008 Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors Int J Gynecol Cancer 18 637 641 17944914 10.1111/j.1525-1438.2007.01116.x 1:STN:280:DC%2BD1crisl2ntw%3D%3D (Pubitemid 352020190)
60. W Schröder M Zimny C Rudlowski U Bull W Rath 1999 The role of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer Int J Gynecol Cancer 9 117 122 11240752 10.1046/j.1525-1438. 1999.09903.x (Pubitemid 29220748)
61. T Kurokawa Y Yoshida K Kawahara T Tsuchida H Okazawa Y Fujibayashi, et al. 2004 Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary Int J Cancer 109 926 932 15027127 10.1002/ijc.20057 1:CAS:528:DC%2BD2cXjt1ens7Y%3D (Pubitemid 38500750)
62. T Kalir BY Wang M Goldfischer RS Haber I Reder R Demopoulos, et al. 2002 Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia Cancer 15 1078 1082 10.1002/cncr.10280 (Pubitemid 34150863)